BTK inhibitors (e.g. ibrutinib) are already being used in human disease for hematologic indications (chronic lymphocytic leukemia and small lymphocytic lymphoma), highlighting the real translational potential of this pathway [27]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.